C eliac disease (CD) is an autoimmune enteropathy triggered by dietary gluten in genetically susceptible individuals.
1 Until a few decades ago, CD was considered to be an uncommon disease affecting mainly children and limited to individuals of European ancestry. 1 In the 1970s, the diagnosis of CD required a sequence of 3 small intestinal biopsies, but the current guidelines suggest that its diagnosis should be based on the combination of a positive celiac-specific serologic test and small intestinal biopsy specimens showing villous abnormalities. 2, 3 Simplification of the diagnostic criteria and widespread use of serologic tests have made it possible to estimate the true prevalence of CD in the general population. 1 Over the past 2 decades, CD has emerged as a major public health problem. Initial prevalence studies in the general population came from European countries and it was estimated to affect approximately 1% of the European population. 4, 5 CD subsequently was reported from other parts of world with predominant Caucasian populations such as North America, Australia, and Brazil. [6] [7] [8] In the past few decades, population-based data on the prevalence of CD also have been reported from the Middle East, India, and so forth. [9] [10] [11] The prevalence of CD-predisposing HLA haplotypes in the general population and per-capita wheat composition, the 2 primary determinants of CD prevalence, vary from one region to the other. 12, 13 However, it is unclear if there is any variation in the prevalence of CD in different parts of the world. Although most reviews on CD suggest that the global prevalence of CD is approximately 1%, there has been no meta-analysis on this topic. 12 A systematic review of the global prevalence of CD by Biagi et al 14 had several limitations including an incomplete review of the literature, a lack of assessment of the quality of studies, and a lack of assessment of the risk of bias or heterogeneity. A few other systematic reviews on this topic had similar limitations and the authors of these systematic reviews did not attempt to pool the data. 15, 16 We therefore conducted a systematic review and meta-analysis of the published studies on the prevalence of CD to estimate the pooled prevalence, and variation in the prevalence, of CD around the world.
Methods
We conducted an extensive search on Medline, PubMed, and EMBASE with the following medical subject heading terms and keywords "celiac disease," "celiac," "coeliac disease," "tissue transglutaminase antibody," "anti-endomysium antibody," "endomysial antibody," and "prevalence." Each one was crossreferenced with "Asia," "Europe," "Africa," "South America," "North America," and "Australia." Because the European Society of Gastroenterology, Hepatology and Nutrition released the first modern guidelines for diagnosis of CD in 1990, we considered the year 1990 as a dividing year for well-defined diagnostic criteria for CD and all relevant articles published from January 1991 to March 2016 were included in this metaanalysis. 17 Studies published after January 1991, with inclusion of study population before January 1991, were excluded from this systematic review. The articles also were identified using a hand search of the references of the studies whose full texts were accessed. There were no language restrictions on the search. Abstracts that were not published as full texts were not included in the present study.
Two authors (P.S. and A.A.) performed the literature search, reviewed all the full texts, and individually decided whether the study should be included or not based on predecided inclusion and exclusion criteria. Disagreements between the 2 authors were resolved by discussion. In case of persistent disagreement, the senior author (G.K.M.) reviewed the study and made the final decision.
Seroprevalence of Celiac Disease
For the present study, seroprevalence of CD in the population was considered as subjects having a positive anti-tissue transglutaminase (tTG) antibody (Ab) and/or anti-endomysial antibodies (AEAs). Because antigliadin antibody (AGA) is no longer recommended in the diagnostic algorithm of CD, studies reporting AGA alone were not considered for the estimation of seroprevalence of CD in the present systematic review. 3 
Diagnosis of Celiac Disease
CD was diagnosed if any of the following criteria were present: a combination of at least 1 positive celiac-specific serologic test such as anti-tTG Ab, AEA, or AGA, and demonstration of histologic changes of modified Marsh grade 2 or more on the small intestinal biopsies; and in the absence of data on celiac-specific serology, a combination of the presence of histologic changes of modified Marsh grade 2 or more on small intestinal biopsies and demonstration of clinical and/or histologic improvement after initiation of a gluten-free diet. 3 
Inclusion Criteria
All of the studies reporting the prevalence of CD in the general population were screened. Studies were included if they reported anti-tTG Ab or AEA as the initial screening test. Studies in which individuals did not undergo a biopsy after positive serology were included to calculate the pooled seroprevalence of CD but not for the pooled prevalence of CD.
Exclusion Criteria
The exclusion criteria included the following: (1) studies in which only high-risk subjects such as those with type 1 diabetes mellitus underwent testing; (2) studies documenting the prevalence based on selfreporting, database, or hospital registries; (3) if multiple studies were performed on the same stored sera, only the latest study was included; and (4) studies using AGA as the first-line or the sole screening test were excluded because AGA is no longer recommended as a sole screening test for CD. 3 However, if AGA was used in combination with either anti-tTG Ab or AEA on all the individuals enrolled in a study, then these studies were included.
Risk of Bias Estimation
The risk of bias was calculated using the risk of bias tool for prevalence studies developed by Hoy et al.
grouped into a low, moderate, or high risk of bias. 18 The studies with a score of less than 6 were considered to have a high risk of bias, 6 to 8 was considered a moderate risk of bias, and 9 to 10 was considered a low risk of bias. The study(s) with a high risk of bias were excluded from the present systematic review.
Data Extraction
Two investigators (P.S. and A.A.) extracted the relevant data independently and the conflicts were resolved by consensus. The following information was extracted from each study: first author, year of publication, study design, number of people screened, type of serology used, number of seropositive participants, participants who underwent small intestinal mucosal biopsies, and results of the biopsies.
Pooled Prevalence of Celiac Disease
For calculation of the pooled prevalence of CD, only studies in which 50% or more of seropositive individuals (those with a positive anti-tTG and/or AEA) underwent a biopsy were included. The cut-off value of 50% was chosen arbitrability because we believed that including the studies in which less than 50% of seropositive individuals underwent a biopsy would falsely lower the actual prevalence of biopsy-proven CD. The studies in which less than 50% of seropositive individuals underwent a biopsy were included for calculation of pooled seroprevalence only.
Statistical Analysis
The meta-analysis was performed in line with the recommendations from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses guidelines. 19 We used the meta package in R, version 3.2.1 (www. r-project.org) using random-effects models. 20 Prevalence and forest plots were generated using the metaprop command. The Freeman-Tukey double-arcsine transformation was used for variance stabilization of proportions. 21 Heterogeneity between studies was expressed by the I 2 statistic and the Cochran Q test for heterogeneity. I 2 values of 0%, less than 25%, 25% to 49% and more than 50% denoted no, low, moderate, and high heterogeneity, respectively. Results were considered significant if the P value was less than .05.
Results
Our search found a total of 3843 articles in the database (Supplementary Figure 1) . Of them, 3674 articles were excluded based on the titles or abstracts. Finally, full texts of 169 articles were assessed. Sixty-four additional studies were excluded based on the inclusion and exclusion criteria. Nine more studies were excluded for several reasons detailed in Supplementary Figure 1 . 4, 5, [22] [23] [24] [25] [26] [27] [28] Ultimately, 96 studies were included in the present meta-analysis (Supplementary Figure 1) . 4, 6, [9] [10] [11] 
Seroprevalence of Celiac Disease
Pooled global seroprevalence of celiac disease. All 96 studies were included for the calculation of the pooled seroprevalence of CD. 4, 6, [9] [10] [11] Of 275,818 individuals, 5571 individuals were reported to be positive for anti-tTG Ab and/or AEA. Thus, the pooled global seroprevalence of CD in the general population was 1.4% (95% confidence interval [CI], 1.1%-1.7%) (Figure 1 ). The I 2 test for heterogeneity was 97.5%, indicating significant heterogeneity among the studies.
Pooled seroprevalence of celiac disease in different continents. Of 96 studies, 49 studies were from Europe, 20 were from Asia, 11 were from South America, 7 were from North America, 7 were from Africa, and 1 was from Australia and New Zealand each. 4, 6, [9] [10] [11] The pooled seroprevalence ranged from 1.1% (95% CI, 0.4%-2.2%) in Africa to 1.8% (95% CI, 1%-2.9%) in Asia ( Table 1) . The I 2 test for heterogeneity ranged from 91% in North America to 99% in Asia.
Pooled Global Prevalence of Celiac Disease
Of 96 studies included in the calculation of pooled seroprevalence, 25 studies were excluded because intestinal mucosal biopsies were not performed. 4, 6, [9] [10] [11] Another 17 studies were excluded because less than 50% of seropositive individuals underwent a biopsy. Finally, 57 studies were included in this part of the analysis. [9] [10] [11] 31, 33, 34, [36] [37] [38] [39] [40] [41] [42] 47, 48, 50, [53] [54] [55] [56] [58] [59] [60] [61] 63, 65, 66, 68, 70, 71, 74, 76, 77, 80, [82] [83] [84] [85] [87] [88] [89] 92, 93, 96, [101] [102] [103] 105, [109] [110] [111] 115, 116 The main characteristics of these 57 studies are described in Table 2 .
Pooled global prevalence of celiac disease. In these 57 studies, a total of 1372 of 138,792 individuals were diagnosed to have biopsy-confirmed CD (Table 2) . Thus, the global pooled prevalence of biopsy-confirmed CD in the present meta-analysis was 0.7% (95% CI, 0.5%-0.9%) ( Figure 2 ). The I 2 test for heterogeneity for this part of the analysis was 92.3%.
Pooled prevalence of celiac disease in different continents. Of the earlier-mentioned 57 studies, 33 studies were from Europe, 12 were from Asia, 5 were from South America, 4 were from Africa, 2 were from Oceania, and only 1 was from North America ( Table 1 ). The pooled prevalence of biopsy-proven CD ranged from 0.5% (95% CI, 0.2%-0.9%) in Africa 11, 31, 33, 34 to 0.8% (95% CI, 0.6%-1.1%) in Europe. [53] [54] [55] [56] [57] [58] [59] [60] [61] 63, 65, 66, 68, 70, 71, 74, 76, 77, 80, [82] [83] [84] [85] [87] [88] [89] [90] [91] [92] [93] 115, 116 Of 7 studies included in the calculation of seroprevalence from North America, 6 ,95-100 biopsies were not performed in 4 studies. 95, 97, 99, 100 In 2 other studies only 22.6% and 26.9% seropositive individuals underwent a biopsy and thus could not be included in this part of the analysis. 6, 98 The study from Cuba screened 200 individuals and found 1 seropositive individual who subsequently had villous atrophy. 96 Therefore, only 1 study could be included from North America for deriving the pooled prevalence of biopsy-confirmed CD. 96 The I 2 test for heterogeneity ranged from 61% in Asia to 94% in Europe.
Country-wise pooled seroprevalence and prevalence of celiac disease. We also calculated the pooled seroprevalence and prevalence of CD for individual countries if the data were available. The countries were stratified into 4 percentile groups (0-25th, 26th-50th, 51st-75th, and 76th-100th).
With regard to seroprevalence, Algeria, Czech Republic, India, Israel, Mexico, Malaysia, Saudi Arabia, Sweden, Portugal, and Turkey belonged to the 76th to 100th percentile (pooled country-wise prevalence, 2.1%-8.5%), whereas Estonia, Germany, Iceland, Libya, Poland, Republic of San Marino, Spain, and Switzerland belonged to the 0 to 25th percentile (pooled countrywise prevalence, 0.2%-0.8%) (Figure 3 ).
When we stratified countries into quintiles based on biopsy-proven CD, Argentina, Egypt, Hungary, Finland, India, New Zealand, and Sweden were in the 76th to 100th percentile (pooled country-wise prevalence, 0.9%-2.4%). Among the countries where data from biopsy-proven CD were available, Brazil, Germany, Republic of San Marino, Russia, and Tunisia were among the 0 to 25th percentile (pooled country-wise prevalence, 0.2%-0.4%) (Figure 4 ).
Gender-Based Difference in the Prevalence of Biopsy-Confirmed Celiac Disease
Only 33 studies reported separate pooled prevalence of biopsy-confirmed CD for males and females. Of 33,149 males and 27,371 females, 156 males (0.4%, 95% CI, 0.3%-0.5%) and 213 females (0.6%; 95% CI, 0.5%-0.8%) were found to have biopsy-confirmed CD (P < .001). 
Difference in the Prevalence of Biopsy-Confirmed Celiac Disease in Children and Adults
Of 57 studies included in the calculation of the pooled prevalence of biopsy-confirmed CD, 43 studies reported a separate pooled prevalence for pediatric and adult CD patients. 10, 11, 31, 33, 34, [36] [37] [38] [39] [40] [41] [42] 47, 48, 50, 53, 56, 57, 59, 61, 65, 66, 68, 70, 76, 77, 80, 82, 83, 85, [88] [89] [90] [91] [92] [93] 101, 102, 105, 109, 111, 116, 117 A total of 276 of 40,076 screened adults had CD, providing a pooled prevalence of 0.5% (95% CI, 0.3-0.8). Of 65,957 screened children, 891 children had CD, with a pooled prevalence of 0.9% (95% CI, 0.6-1.3), which was higher than that in adults (P < .001). The I 2 test for heterogeneity was 94% among children and 89% among adults. 
Exploring Heterogeneity
To explore heterogeneity further, we also grouped the studies based on the proportion (50%-74.9%, 75%-99.9%, and 100%) of seropositive individuals who underwent duodenal biopsies. However, heterogeneity did not seem to vary based on the proportion of seropositive individuals undergoing biopsies (results shown in the Supplementary Materials and Methods section). In addition, studies were also grouped based on the risk of bias (low or moderate). This also did not explain the heterogeneity (results shown in the Supplementary Materials and Methods section). Furthermore, we grouped studies into 2 groups: truly population-based and those that were not (studies based on healthy blood donors, school children, and so forth). Heterogeneity was similar in these 2 groups (results shown in the Supplementary Materials and Methods section).
Prevalence Over Time
To assess if the prevalence of CD is increasing over time, we stratified the studies into 2 time periods: January 1991 to December 2000 and January 2001 onward (based on the actual study period). The studies that overlapped these 2 time periods were removed from the analysis. The pooled prevalence of CD during the duration from 1991 to 2000 was 0.6% (95% CI, 0.5%-0.7%). [53] [54] [55] [56] [57] [58] [59] [60] [61] 63, 65, 66, 68, 76, [101] [102] [103] 116 The I 2 test for heterogeneity was reduced significantly to 67% in this group. The pooled global prevalence of CD between January 2011 and March 2016 was 0.8% (95% CI, 0.5%-1%), suggesting an increase in the prevalence of CD over time. 9, 11, 31, 33, 37, [39] [40] [41] [42] 47, 48, 74, 77, 80, 82, 84, 85, 87, [89] [90] [91] [92] [93] 97, 105, 109, 111 The heterogeneity for this group was 94%.
Discussion
The present meta-analysis showed that the pooled global seroprevalence of CD is 1.4% (95% CI, 1.1%-1.7%). The pooled global prevalence of biopsy-confirmed CD is 0.7% (95% CI, 0.5%-0.9%), with the highest prevalence in Europe (0.8%) and Oceania (0.8%), and the least prevalence in South America (0.4%). The present meta-analysis confirms that biopsy-confirmed CD is 1.5 times more common in females than in males, and approximately twice more common in children than in adults.
In our study, the pooled prevalence of biopsyconfirmed CD was 0.7% (95% CI, 0.5%-0.9%). This is slightly higher than that reported by Biagi et al 14 (0.58%) and likely is owing to more rigorous literature search, methodology, and detailed analysis in the present study. Of such a large pool of patients with CD globally, the majority of patients (83%-95%) in developed countries, and possibly even a higher number in developing countries, still remain undiagnosed. Includes data from Iran, Turkey, Saudi Arabia, Israel, Jordan, and Egypt. All of these countries except Egypt have been included in Asia.
98,118
c Includes data from India and Malaysia. Data from both of these countries are included in Asia.
d
Includes data from Tunisia, Libya, Algeria, and Burkina Faso. All of these countries along with Egypt constitute the data from Africa. The prevalence of CD varies from 0.4% in South America to 0.8% in Europe and Oceania. The factors responsible for this difference likely are genetic (including HLA and non-HLA genes), and environmental including patterns of wheat consumption, age at wheat introduction, infant feeding practices, gastrointestinal infections, antibiotic and proton-pump inhibitor use, and caesarian section rates. 119 The prevalence of CD in a few geographic regions warrants some discussion. Although 1.4% of the North American population were seropositive for CD in the present meta-analysis, the exact proportion of biopsyconfirmed CD could not be established, mostly because seropositive individuals did not undergo a biopsy at all or fewer than 50% underwent a biopsy.
The seroprevalence of CD was observed to be highest in Asia (1.8%) and lowest in Africa (1.1%). In Africa, the population prevalence of the HLA-DQ2 haplotype and wheat consumption are significantly lower in subSaharan Africa compared with Northern Africa. 120 Thus, it is very likely that the majority of the sub-Saharan population is less susceptible to CD than in other parts of Africa. The only study from sub-Saharan Africa was from Burkina-Faso, where 600 individuals from the general population were screened and none were found to be seropositive for CD. 30 The studies from Africa are generally from the Northern parts of Africa and thus the data from this systematic review mainly represent the prevalence from this region of the continent.
In addition, of the world's top 10 most populous countries, population-based prevalence data on CD are available only from 4 countries (India, United States, Brazil, and Russia). Population-based prevalence data from the other 6 most populous countries (China, Indonesia, Pakistan, Nigeria, Bangladesh, and Japan) are lacking, although CD has been reported in each of these countries except Nigeria. There is a need for well-designed, population-based studies from many parts of the world. With a population of 143 million, reports on the prevalence of CD from Russia are sparse. Two small studies from Russia have screened a total of 3728 individuals with a seroprevalence of 1.4%, a prevalence closer to that observed in other parts of the world. 75, 83 There is a possibility of a large burden of CD in Russia, which needs to be explored.
What explains the difference between the pooled global seroprevalence of CD (1.4%) and the pooled global prevalence of biopsy-confirmed CD (0.7%)? We only included studies if at least 50% of the seropositive individuals underwent a biopsy for the calculation of the prevalence of CD. Still, there was a wide variation in the rate of seropositive individuals who underwent a biopsy and it ranged from 51.2% to 100%. This could have led to an underestimation of actual CD prevalence. In addition, some of these seropositive individuals may have had a false-positive screening test.
We noted several limitations of the estimates. First, there was a lack of population-based prevalence data from many countries across the world, and many of the available studies suffered from limitations such as a lack of an adequate number of subjects, lack of data on sex and age, and nonrandom sampling of the population at large. Second, many studies have reported a prevalence of CD based on the serology alone and even if the biopsies were performed in seropositive individuals, only a small proportion underwent biopsies. We therefore included only those studies in which at least 50% of subjects had undergone biopsies for reporting the prevalence of biopsy-confirmed CD. Similarly, we have no data on seronegative CD from these studies and therefore the pooled prevalence of CD in the present meta-analysis could be an underestimate of the exact prevalence of CD.
In conclusion, CD is a global disease and the global seroprevalence and prevalence of CD are 1.4% and 0.7%, respectively. The prevalence of CD varies with sex, age, and geographic location. The prevalence of CD has increased over time from 0.6% in 1991 to 2000 to 0.8% between 2001 and 2016. There is a need for populationbased prevalence studies in many countries to estimate the global burden of CD properly.
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